155 related articles for article (PubMed ID: 32916470)
1. Preclinical evaluation of new α-radionuclide therapy targeting LAT1: 2-[
Ohshima Y; Suzuki H; Hanaoka H; Sasaki I; Watanabe S; Haba H; Arano Y; Tsushima Y; Ishioka NS
Nucl Med Biol; 2020; 90-91():15-22. PubMed ID: 32916470
[TBL] [Abstract][Full Text] [Related]
2. Enhancing the Therapeutic Effect of 2-
Hanaoka H; Ohshima Y; Suzuki H; Sasaki I; Watabe T; Ooe K; Watanabe S; Ishioka NS
Cancers (Basel); 2021 Nov; 13(21):. PubMed ID: 34771676
[TBL] [Abstract][Full Text] [Related]
3. Novel
Hanaoka H; Ohshima Y; Yamaguchi A; Suzuki H; Ishioka NS; Higuchi T; Arano Y; Tsushima Y
Mol Pharm; 2019 Aug; 16(8):3609-3616. PubMed ID: 31242385
[TBL] [Abstract][Full Text] [Related]
4. α-Emitting cancer therapy using
Kaneda-Nakashima K; Zhang Z; Manabe Y; Shimoyama A; Kabayama K; Watabe T; Kanai Y; Ooe K; Toyoshima A; Shirakami Y; Yoshimura T; Fukuda M; Hatazawa J; Nakano T; Fukase K; Shinohara A
Cancer Sci; 2021 Mar; 112(3):1132-1140. PubMed ID: 33277750
[TBL] [Abstract][Full Text] [Related]
5. Transport of 3-fluoro-L-α-methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: a cause of the tumor uptake in PET.
Wiriyasermkul P; Nagamori S; Tominaga H; Oriuchi N; Kaira K; Nakao H; Kitashoji T; Ohgaki R; Tanaka H; Endou H; Endo K; Sakurai H; Kanai Y
J Nucl Med; 2012 Aug; 53(8):1253-61. PubMed ID: 22743251
[TBL] [Abstract][Full Text] [Related]
6. Development of a Widely Usable Amino Acid Tracer: ⁷⁶Br-α-Methyl-Phenylalanine for Tumor PET Imaging.
Hanaoka H; Ohshima Y; Suzuki Y; Yamaguchi A; Watanabe S; Uehara T; Nagamori S; Kanai Y; Ishioka NS; Tsushima Y; Endo K; Arano Y
J Nucl Med; 2015 May; 56(5):791-7. PubMed ID: 25814518
[TBL] [Abstract][Full Text] [Related]
7. Distribution of LAT1-targeting PET tracer was independent of the tumor blood flow in rat xenograft models of C6 glioma and MIA PaCa-2.
Aoki M; Watabe T; Nagamori S; Naka S; Ikeda H; Kongpracha P; Horitsugi G; Kanai Y; Shimosegawa E; Kanai Y; Hatazawa J
Ann Nucl Med; 2019 Jun; 33(6):394-403. PubMed ID: 30820863
[TBL] [Abstract][Full Text] [Related]
8. Imaging the L-type amino acid transporter-1 (LAT1) with Zr-89 immunoPET.
Ikotun OF; Marquez BV; Huang C; Masuko K; Daiji M; Masuko T; McConathy J; Lapi SE
PLoS One; 2013; 8(10):e77476. PubMed ID: 24143237
[TBL] [Abstract][Full Text] [Related]
9.
Watabe T; Ikeda H; Nagamori S; Wiriyasermkul P; Tanaka Y; Naka S; Kanai Y; Hagiwara K; Aoki M; Shimosegawa E; Kanai Y; Hatazawa J
Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):321-331. PubMed ID: 27550420
[TBL] [Abstract][Full Text] [Related]
10. Targeted alpha therapy using astatine (
Watabe T; Kaneda-Nakashima K; Shirakami Y; Liu Y; Ooe K; Teramoto T; Toyoshima A; Shimosegawa E; Nakano T; Kanai Y; Shinohara A; Hatazawa J
Oncotarget; 2020 Apr; 11(15):1388-1398. PubMed ID: 32341757
[TBL] [Abstract][Full Text] [Related]
11. In vivo characterization of 123/125I-2-iodo-L-phenylalanine in an R1M rhabdomyosarcoma athymic mouse model as a potential tumor tracer for SPECT.
Kersemans V; Cornelissen B; Kersemans K; Bauwens M; Achten E; Dierckx RA; Mertens J; Slegers G
J Nucl Med; 2005 Mar; 46(3):532-9. PubMed ID: 15750170
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity characteristics of phenylalanine analogs selectively transported by L-type amino acid transporter 1 (LAT1).
Chen S; Jin C; Ohgaki R; Xu M; Okanishi H; Kanai Y
Sci Rep; 2024 Feb; 14(1):4651. PubMed ID: 38409393
[TBL] [Abstract][Full Text] [Related]
13. Large Amino Acid Transporter 1 Selective Liposomes of l-DOPA Functionalized Amphiphile for Combating Glioblastoma.
Bhunia S; Vangala V; Bhattacharya D; Ravuri HG; Kuncha M; Chakravarty S; Sistla R; Chaudhuri A
Mol Pharm; 2017 Nov; 14(11):3834-3847. PubMed ID: 28958145
[TBL] [Abstract][Full Text] [Related]
14. Structural properties for selective and efficient l-type amino acid transporter 1 (LAT1) mediated cellular uptake.
Kärkkäinen J; Gynther M; Kokkola T; Petsalo A; Auriola S; Lahtela-Kakkonen M; Laine K; Rautio J; Huttunen KM
Int J Pharm; 2018 Jun; 544(1):91-99. PubMed ID: 29669256
[TBL] [Abstract][Full Text] [Related]
15. Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): insights into the mechanisms of substrate recognition.
Uchino H; Kanai Y; Kim DK; Wempe MF; Chairoungdua A; Morimoto E; Anders MW; Endou H
Mol Pharmacol; 2002 Apr; 61(4):729-37. PubMed ID: 11901210
[TBL] [Abstract][Full Text] [Related]
16. The pre-clinical characterization of an alpha-emitting sigma-2 receptor targeted radiotherapeutic.
Makvandi M; Lieberman BP; LeGeyt B; Hou C; Mankoff DA; Mach RH; Pryma DA
Nucl Med Biol; 2016 Jan; 43(1):35-41. PubMed ID: 26702785
[TBL] [Abstract][Full Text] [Related]
17. Biological evaluation of 3-[(18)F]fluoro-α-methyl-D-tyrosine (D-[(18)F]FAMT) as a novel amino acid tracer for positron emission tomography.
Ohshima Y; Hanaoka H; Tominaga H; Kanai Y; Kaira K; Yamaguchi A; Nagamori S; Oriuchi N; Tsushima Y; Endo K; Ishioka NS
Ann Nucl Med; 2013 May; 27(4):314-24. PubMed ID: 23337966
[TBL] [Abstract][Full Text] [Related]
18. A new treatment for human malignant melanoma targeting L-type amino acid transporter 1 (LAT1): a pilot study in a canine model.
Fukumoto S; Hanazono K; Fu DR; Endo Y; Kadosawa T; Iwano H; Uchide T
Biochem Biophys Res Commun; 2013 Sep; 439(1):103-8. PubMed ID: 23954667
[TBL] [Abstract][Full Text] [Related]
19. The role of LAT1 in (18)F-DOPA uptake in malignant gliomas.
Youland RS; Kitange GJ; Peterson TE; Pafundi DH; Ramiscal JA; Pokorny JL; Giannini C; Laack NN; Parney IF; Lowe VJ; Brinkmann DH; Sarkaria JN
J Neurooncol; 2013 Jan; 111(1):11-8. PubMed ID: 23086431
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor effects of mAb against L-type amino acid transporter 1 (LAT1) bound to human and monkey LAT1 with dual avidity modes.
Ueda S; Hayashi H; Miyamoto T; Abe S; Hirai K; Matsukura K; Yagi H; Hara Y; Yoshida K; Okazaki S; Tamura M; Abe Y; Agatsuma T; Niwa SI; Masuko K; Masuko T
Cancer Sci; 2019 Feb; 110(2):674-685. PubMed ID: 30548114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
